Literature DB >> 28470585

Evaluation of Radioiodinated 1,4-Naphthoquinones as Necrosis Avid Agents for Rapid Myocardium Necrosis Imaging.

Chang Su1,2,3, Dongjian Zhang2,3, Na Bao1, Aiyan Ji1,2,3, Yuanbo Feng2,3,4, Li Chen1, Yicheng Ni2,3,4, Jian Zhang5,6, Zhiqi Yin7.   

Abstract

PURPOSE: Identifying necrotic myocardium in ischemic regions is of great importance for risk stratification and clinical decision-making. However, rapid noninvasive imaging of necrotic myocardium is still challenging. This study sought to evaluate the potential of 1,4-naphthoquinones to rapidly visualize necrotic myocardium and the possible mechanisms of necrosis avidity. PROCEDURES: Six 1,4-naphthoquinones were radiolabeled with iodine-131 and the necrosis avidity was estimated in mouse models with muscular necrosis by gamma counting and autoradiography. The necrotic myocardium imaging property and biodistribution of [131I]naphthazarin (6) were determined in rat models with re-perfused myocardial infarction. A possible mechanism of necrosis avidity was explored by in vitro DNA-binding and in vivo blocking experiments.
RESULTS: The radiochemical purities of the six radiotracers were greater than 95 %. The uptakes in necrotic muscles of all six radiotracers were higher than those in viable muscles, and [131I]naphthazarin (6) showed the highest necrotic-to-viable ratio and necrosis-to-blood ratio at all tested time points. The necrotic myocardium could be clearly visualized by single-photon emission computed tomography/x-ray computed tomography (SPECT/CT) using [131I]naphthazarin (6) as early as 3 h post-injection. Post-mortem biodistribution showed the uptake of [131I]naphthazarin (6) in necrotic myocardium was 11.67-fold higher than that in viable myocardium. Absorption spectra and emission spectra suggested naphthazarin (6) could bind to DNA through intercalation. The uptake of [131I]naphthazarin (6) in necrotic muscle could be significantly blocked by excessive ethidium bromide (a typical DNA intercalator) and cold naphthazarin (6) with 63.49 and 71.96 % decline at 3 h post-injection in vivo, respectively.
CONCLUSIONS: 1,4-Naphthoquinones retained necrosis avidity and [131I]naphthazarin (6) rapidly visualized necrotic myocardium. The necrosis avidity mechanism of [131I]naphthazarin (6) may be attributed to its binding with exposed DNA in necrotic tissues.

Entities:  

Keywords:  1,4-Naphthoquinones; Blood clearance; DNA intercalation; Necrosis avidity; Necrotic myocardium

Mesh:

Substances:

Year:  2018        PMID: 28470585     DOI: 10.1007/s11307-017-1089-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  30 in total

1.  MALDI mass spectrometric imaging of cardiac tissue following myocardial infarction in a rat coronary artery ligation model.

Authors:  Robert F Menger; Whitney L Stutts; Dhanalakshmi S Anbukumar; John A Bowden; David A Ford; Richard A Yost
Journal:  Anal Chem       Date:  2011-12-22       Impact factor: 6.986

Review 2.  Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling.

Authors:  Antonio Rescifina; Chiara Zagni; Maria Giulia Varrica; Venerando Pistarà; Antonino Corsaro
Journal:  Eur J Med Chem       Date:  2014-01-03       Impact factor: 6.514

Review 3.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 4.  The current role of infarct avid imaging.

Authors:  B A Khaw
Journal:  Semin Nucl Med       Date:  1999-07       Impact factor: 4.446

5.  Radiopharmaceutical evaluation of (131)I-protohypericin as a necrosis avid compound.

Authors:  Xuejiao Liu; Yuanbo Feng; Cuihua Jiang; Bin Lou; Yue Li; Wei Liu; Nan Yao; Meng Gao; Yun Ji; Qingqing Wang; Dejian Huang; Zhiqi Yin; Ziping Sun; Yicheng Ni; Jian Zhang
Journal:  J Drug Target       Date:  2015-02-06       Impact factor: 5.121

6.  Syntheses, characterization and DNA-binding studies of ruthenium(II) terpyridine complexes: [Ru(tpy)(PHBI)]2+ and [Ru(tpy)(PHNI)]2+.

Authors:  Cai-Wu Jiang; Hui Chao; Hong Li; Liang-Nian Ji
Journal:  J Inorg Biochem       Date:  2003-01-15       Impact factor: 4.155

7.  Organometallic ruthenium(II) complexes: synthesis, structure and influence of substitution at azomethine carbon towards DNA/BSA binding, radical scavenging and cytotoxicity.

Authors:  Palanisamy Sathyadevi; Paramasivam Krishnamoorthy; Nattamai S P Bhuvanesh; Palaniswamy Kalaiselvi; Viswanadha Vijaya Padma; Nallasamy Dharmaraj
Journal:  Eur J Med Chem       Date:  2012-08-10       Impact factor: 6.514

8.  Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT.

Authors:  Humphrey Fonge; Kathleen Vunckx; Huaijun Wang; Yuanbo Feng; Luc Mortelmans; Johan Nuyts; Guy Bormans; Alfons Verbruggen; Yicheng Ni
Journal:  Eur Heart J       Date:  2007-12-20       Impact factor: 29.983

9.  The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion.

Authors:  M C Fishbein; J Y-Rit; U Lando; K Kanmatsuse; J C Mercier; W Ganz
Journal:  Circulation       Date:  1980-12       Impact factor: 29.690

10.  Discovery of Radioiodinated Monomeric Anthraquinones as a Novel Class of Necrosis Avid Agents for Early Imaging of Necrotic Myocardium.

Authors:  Qin Wang; Shengwei Yang; Cuihua Jiang; Jindian Li; Cong Wang; Linwei Chen; Qiaomei Jin; Shaoli Song; Yuanbo Feng; Yicheng Ni; Jian Zhang; Zhiqi Yin
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

View more
  2 in total

Review 1.  The evolving roles of radiolabeled quinones as small molecular probes in necrotic imaging.

Authors:  Chang Su; Yan Xu
Journal:  Br J Radiol       Date:  2020-05-21       Impact factor: 3.039

2.  Updated developments on molecular imaging and therapeutic strategies directed against necrosis.

Authors:  Dongjian Zhang; Meng Gao; Qiaomei Jin; Yicheng Ni; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2019-02-13       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.